Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
Metrics to compare | 2592 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2592PeersSector | |
---|---|---|---|---|
P/E Ratio | −6.0x | −0.6x | −0.7x | |
PEG Ratio | - | −0.09 | 0.00 | |
Price/Book | −0.8x | 1.7x | 2.6x | |
Price / LTM Sales | 24.5x | 9.2x | 3.4x | |
Upside (Analyst Target) | - | 173.9% | 38.0% | |
Fair Value Upside | Unlock | 16.0% | 5.2% | Unlock |